Pharmacologic Resistance in Prolactinoma Patients
- 1 January 2005
- journal article
- review article
- Published by Springer Nature in Pituitary
- Vol. 8 (1) , 43-52
Abstract
Pharmacologic resistance to dopamine agonists is defined here as failure to normalize PRL levels and failure to decrease macroprolactinoma size by ≥50%. Failure to normalize PRL levels is found in about one-quarter of patients treated with bromocriptine and 10–15% of those treated with pergolide or cabergoline. Failure to achieve at least a 50% reduction in tumor size occurs in about one-third of those treated with bromocriptine and 10–15% of those treated with pergolide or cabergoline. The cause of dopamine resistance is primarily a decrease in D2 receptors but the receptors have normal affinity for dopamine. Treatment approaches for patients resistant to dopamine agonists include changing to another dopamine agonist and increasing the dose of the drug as long as there is continued response to the dose increases and no adverse effects with higher doses. Transsphenoidal surgery is also an option. Clomiphene, gonadotropins, and GnRH can be used if fertility is desired. For those not desiring fertility, estrogen replacement may be used unless there is a macroadenoma, in which case control of tumor growth is also an issue and dopamine agonists are generally necessary. In many patients modest or even no reduction in tumor size may be acceptable as long as there is not tumor growth. Hormone replacement (estrogen or testosterone) may cause a decrease in efficacy of the dopamine agonist so that it must be carried out cautiously. Reduction of endogenous estrogen, use of selective estrogen receptor modulators, and aromatase inhibitors are potential experimental approaches.Keywords
This publication has 110 references indexed in Scilit:
- Alteration of Gα Subunits mRNA Levels in Bromocriptine Resistant ProlactinomasJournal of Neuroendocrinology, 1996
- Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuationsNeurology, 1996
- Low Doses of Dopamine Agonists in the Long-Term Treatment of MacroprolactinomasNew England Journal of Medicine, 1985
- Hormonal Regulation of Prolactin Release by Human Prolactinoma Cells Cultured in Serum-Free ConditionsHormone Research, 1985
- Pergolide for the Treatment of Pituitary Tumors Secreting Prolactin or Growth HormoneNew England Journal of Medicine, 1983
- Effect of Tamoxifen Administration on Prolactin Release by Invasive Prolactin-Secreting Pituitary AdenomasNeuroendocrinology, 1982
- TAMOXIFEN SUPPRESSES BOTH THE GROWTH OF PROLACTIN-SECRETING PITUITARY TUMOURS AND NORMAL PROLACTIN SYNTHESIS IN THE RATJournal of Endocrinology, 1980
- Effect of Antiestrogens on Pituitary Prolactin Production in Normal and Pituitary Tumor-Bearing RatsNeuroendocrinology, 1980
- THE USE OF BROMOCRIPTINE IN THE GALACTORRHOEA‐AMENORRHOEA SYNDROMES: THE CANADIAN COOPERATIVE STUDYClinical Endocrinology, 1977
- Effects of oestrogen and bromocryptine on in vivo secretion and mitosis in prolactin cellsNature, 1975